cbdMD (NYSEAMERICAN:YCBD – Get Free Report) issued its quarterly earnings data on Thursday. The company reported ($0.11) earnings per share for the quarter, missing the consensus estimate of ($0.03) by ($0.08), FiscalAI reports. The company had revenue of $5.55 million during the quarter, compared to the consensus estimate of $5.69 million. cbdMD had a negative net margin of 13.29% and a negative return on equity of 33.60%.
cbdMD Stock Down 5.5%
cbdMD stock traded down $0.03 during trading hours on Thursday, hitting $0.56. The company had a trading volume of 197,695 shares, compared to its average volume of 1,020,979. The firm has a 50-day moving average of $0.64 and a 200 day moving average of $0.74. cbdMD has a one year low of $0.47 and a one year high of $2.56.
Hedge Funds Weigh In On cbdMD
A hedge fund recently bought a new position in cbdMD stock. Jane Street Group LLC acquired a new position in shares of cbdMD, Inc. (NYSEAMERICAN:YCBD – Free Report) during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm acquired 51,141 shares of the company’s stock, valued at approximately $69,000. Jane Street Group LLC owned 0.49% of cbdMD at the end of the most recent reporting period. Hedge funds and other institutional investors own 7.18% of the company’s stock.
cbdMD Company Profile
cbdMD, Inc (NYSEAMERICAN: YCBD) is a Charlotte, North Carolina–based producer and distributor of hemp-derived cannabidiol (CBD) products. Since its founding in 2018, the company has focused on developing a diverse portfolio of wellness offerings designed for human and pet use. Its product range includes tinctures, capsules, gummies, topicals, and pet-specific formulations, each developed to comply with U.S. Food and Drug Administration (FDA) guidelines for hemp-derived substances.
The company operates a vertically integrated business model, sourcing U.S.-grown hemp and overseeing manufacturing processes in cGMP-certified facilities.
Featured Stories
- Five stocks we like better than cbdMD
- Asian Market Circuit Breakers Hit Stocks, Not AI Demand
- Riot Platforms Re-Wires the Ledger for a $9B AI Power Play
- Nebius Just Exploded 34% on Blowout Earnings—Is It Time to Buy?
- Joby’s Defense Pivot Accelerates With $500M Resonant Sciences Deal
Receive News & Ratings for cbdMD Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for cbdMD and related companies with MarketBeat.com's FREE daily email newsletter.
